Literature DB >> 1919529

Neutralizing activity of anti-peptide antibodies against the principal neutralization domain of human immunodeficiency virus type 1.

J P Langedijk1, N K Back, P J Durda, J Goudsmit, R H Meloen.   

Abstract

Monoclonal antibodies (MAbs) raised against a 15-mer peptide representing the centre of the principal neutralization domain of human immunodeficiency virus type 1 (strain BH10) showed wide variations in neutralizing activity against the homologous strain. The nature of this difference in neutralizing activity was studied by measuring antibody concentration, their affinity for peptide and specificity, by reaction with peptides which differed in the extent of sequence overlap, length and the presence of single amino acid replacements. All MAbs bound to approximately the same region in the principal neutralization domain, within the sequence RIQRGPGRAFV. The peptides with which each antibody was able to react differed by only a few amino acids. The neutralizing activity of each MAb preparation was related to its affinity and concentration; the affinity is related in part to the fine structure of the epitope recognized. MAbs with high affinity for the peptide tended to react only with peptides in which amino acid replacements did not affect the beta-turn potential of the peptide, whereas the reactivity of MABs with low affinity was relatively insensitive to amino acid replacements affecting the beta-turn potential.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1919529     DOI: 10.1099/0022-1317-72-10-2519

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  10 in total

1.  Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.

Authors:  J D Laman; M M Schellekens; Y H Abacioglu; G K Lewis; M Tersmette; R A Fouchier; J P Langedijk; E Claassen; W J Boersma
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

2.  Human immunodeficiency virus type 1-like DNA sequences and immunoreactive viral particles with unique association with breast cancer.

Authors:  E M Rakowicz-Szulczynska; B Jackson; A M Szulczynska; M Smith
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

3.  Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1.

Authors:  J P Langedijk; N K Back; E Kinney-Thomas; C Bruck; M Francotte; J Goudsmit; R H Meloen
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

4.  Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.

Authors:  G R Nakamura; R Byrn; D M Wilkes; J A Fox; M R Hobbs; R Hastings; H C Wessling; M A Norcross; B M Fendly; P W Berman
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity.

Authors:  J J de Jong; J Goudsmit; W Keulen; B Klaver; W Krone; M Tersmette; A de Ronde
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

6.  Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies.

Authors:  N K Back; L Smit; M Schutten; P L Nara; M Tersmette; J Goudsmit
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

7.  Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies.

Authors:  E Hogervorst; J de Jong; A van Wijk; M Bakker; M Valk; P Nara; J Goudsmit
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

8.  The HIV-1 V3 domain on field isolates: participation in generation of escape virus in vivo and accessibility to neutralizing antibodies.

Authors:  M Arendrup; L Akerblom; P M Heegaard; J O Nielsen; J E Hansen
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

9.  Novel family of gynecologic cancer antigens detected by anti-HIV antibody.

Authors:  E M Rakowicz-Szulczynska; D G McIntosh; P Morris; M Smith
Journal:  Infect Dis Obstet Gynecol       Date:  1994

Review 10.  Strategies for mapping and imitating viral B-cell epitopes.

Authors:  J Cason
Journal:  J Virol Methods       Date:  1994-09       Impact factor: 2.014

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.